KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Gains from Sales and Divestitures (2019 - 2025)

TherapeuticsMD (TXMD) has disclosed Gains from Sales and Divestitures for 8 consecutive years, with $2000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Sales and Divestitures fell 94.74% year-over-year to $2000.0, compared with a TTM value of $2000.0 through Sep 2025, down 94.74%, and an annual FY2024 reading of $38000.0, up 442.86% over the prior year.
  • Gains from Sales and Divestitures was $2000.0 for Q3 2025 at TherapeuticsMD, roughly flat from $2000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $2.0 million in Q3 2021 and bottomed at $7.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 5 years is $227822.3, with a median of $38000.0 recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures plummeted 99.68% in 2022, then soared 28471.43% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $103000.0 in 2021, then tumbled by 99.68% to $327.0 in 2022, then surged by 2040.67% to $7000.0 in 2023, then soared by 442.86% to $38000.0 in 2024, then plummeted by 94.74% to $2000.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for TXMD at $2000.0 in Q3 2025, $2000.0 in Q2 2025, and $2000.0 in Q1 2025.